Abstract
BACKGROUND: Finding the optimum vascular grafts (VG) to replace damaged blood arteries in cardiac surgery is still a work in progress. To be employed, a tissue-engineered VG (TEVG) must have the appropriate biological and mechanical qualities. Decellularized arteries may be a better TEVG than synthetic grafts because of their natural three-dimensional architecture.
AIM: The goal of this study was to compare different concentrations and times of sodium dodecyl sulfate (SDS) to decellularize tissue to find the best decellularized VG.
METHODS: In all decellularized scaffolds, which are 1% SDS-2 weeks group, hematoxylin and eosin and Masson’s trichrome staining exhibited looser collagen networks and fewer nuclei.
RESULTS: The orientation of collagen fibers was identical to native vascular scaffolds. Collagen I deposition was seen in the immunohistochemistry assay. A tensile strength test revealed that the decellularized scaffold (0.5% SDS for 4 weeks and 0.5% SDS for 2 weeks) had exceeded the native arteries’ maximal strength. In comparison to 1% SDS in 4 weeks treated groups, scanning electron microscopy following decellularization revealed no endothelial cells on the inner side of 1% SDS in 2 weeks group with minimum extracellular matrix damage. The endothelial cells remained marginally visible on the inner side of all 0.5% SDS treated groups. The 3-(4,5-dimethylthiazol-2yl)2,5-diphenyltetrazolium bromide test was used to determine the cytotoxicity of the decellularized scaffolds.
CONCLUSION: This study reveals that exposing a bovine mesenteric artery to 1% SDS for 2 weeks is an excellent procedure for extracting the most acellular VG, potentially serving as a biological scaffold for TEVGs.
Publisher
Scientific Foundation SPIROSKI
Reference26 articles.
1. Sembiring YE, Wijaya RP, Prasmono A, Soebroto H, Sediono OR, et al. Comparation of bovine mesenteric artery with bovine mesenteric vein patency as xenograft in oryctolagus cuniculus carotid artery. Eur J Mol Clin Med. 2021;7(10):3356-61. Available from: https://ejmcm.com/article_7205.html%0Ahttps://ejmcm.com/pdf_7205_b08892c274e3d665f5937be673849950.html [Last accessed on 2022 Jan 22].
2. Baim DS. Percutaneous treatment of saphenous vein graft disease: The ongoing challenge. J Am Coll Cardiol. 2003;42(8):1370-2. https://doi.org/10.1016/s0735-1097(03)01039-8 PMid:14563576
3. Kannan RY, Salacinski HJ, Butler PE, Hamilton G, Seifalian AM. Current status of prosthetic bypass grafts: A review. J Biomed Mater Res B Appl Biomater. 2005;74(1):570-81. https://doi.org/10.1002/jbm.b.30247 PMid:15889440
4. Kumar VA, Brewster LP, Caves JM, Chaikof EL. Tissue engineering of blood vessels: Functional requirements, progress, and future challenges. Cardiovasc Eng Technol. 2011;2(3):137-48. https://doi.org/10.1007/s13239-011-0049-3 PMid:23181145
5. Mallis P, Kostakis A, Stavropoulos-Giokas C, Michalopoulos E. Future perspectives in small-diameter vascular graft engineering. Bioengineering. 2020;7(4):160. https://doi.org/10.3390/bioengineering7040160 PMid:33321830